Search

everythinglearnresearchcommunity

for

Search:↓

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

The user is considering PRP with exosomes for hair loss after oral minoxidil and dutasteride failed to provide desired results. Despite suggestions for a hair transplant, the user is hesitant due to cost and complexity, and is unsure about other options.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

The conversation discusses the appearance of hair transplants immediately after surgery, noting that scars will be covered as hair grows. The original poster underwent both FUT and FUE procedures.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.

The user takes 1 mg finasteride three times a week, topical minoxidil daily, and Saw Palmetto both topically and orally on non-finasteride days. They recently added 1 g of pumpkin seed oil daily to improve hair thickness and are seeking advice on dosing and cycling Saw Palmetto.

Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.

A user's success story of improving their hair loss with treatments that include finasteride, dutasteride, minoxidil, nizoral, and dermastamping; other products that have been tried with varying results; and potential side effects.

Setipiprant may help with hair maintenance but is not a guaranteed solution for everyone. Other treatments like minoxidil, finasteride, and topical spironolactone are discussed, with varying opinions on their effectiveness.

Dr. Gabel doesn't use Verteporfin because it's not FDA approved. The user is getting FUT and wants to minimize scarring and maximize hair regrowth.

Hair loss treatments discussed include Minoxidil, finasteride, and RU58841. Concerns were raised about delays in product presentations and business strategies.

A user shared their experience with Finasteride for hair loss, noting improvement but still some thinning. They plan to get a hair transplant to address remaining thin spots and strengthen their hairline.

The conversation discusses the need for more support and awareness for Verteporfin research in hair loss treatment, emphasizing its potential benefits and quick implementation due to existing FDA approval. Users express skepticism due to past scams but acknowledge the importance of encouraging doctors to conduct trials.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

The user tried various treatments for hair loss, including finasteride, vitamins, Saw Palmetto, beta sitosterol, pumpkin oil, borage oil, stinging nettle, and emu oil. They recently noticed tiny black hairs, suggesting some improvement.

The conversation is about the progress and development of a hair loss treatment called GT20029. People are discussing updates on its status and speculating on how long it will take to become available.

The user shared progress on hair regrowth using a topical minoxidil/finasteride spray, dermarolling weekly, and a product similar to pp405. They reported some regrowth with no side effects from the new product.

A user shared their positive experience with Laq herbal shampoo and Sevich Batana oil for hair loss due to PCOS and an unbalanced diet. They noticed significant improvement after three weeks of using these products.

A user's experience with hair loss treatments, including finasteride and other options such as RU58841, Nizoral, Pumpkin Seed, and Adenosine; the importance of being in a positive frame of mind when considering taking finasteride; and the need to address life issues before starting finasteride.

User quit minoxidil and finasteride, starting stemoxydine, dermastamp, and dermapen for hair loss. Seeks advice on alternatives, avoiding androgen disruptors and vasodilators/vasoconstrictors.

Topical spiro's effectiveness on androgens is discussed. User tried oral DUT, oral Min, keto/nizoral, and RU but experienced worsening hair loss and chest pains. Suggestion given to increase dutasteride and oral minoxidil dosage before considering spironolactone.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

A user shared their 20-week progress using topical minoxidil (5%) and finasteride (0.1%) with a 1mm dermastamp, showing significant hair regrowth from NW5 to between NW3V and NW4. They experienced no side effects and plan to update at 12 months.

A user struggled with hair loss and ineffective vitamin treatments from their doctor. They eventually obtained a finasteride prescription through a telemedicine service and felt relieved.